Not only creating a Covid-19 vaccine, AstraZeneca is also developing drugs for rare diseases. The development has entered its final stages of testing and shows that its artificial cure for a rare disease that causes copper buildup in the body is three times more successful at helping clear the buildup from tissue than conventional treatments.
A drug developed by rare disease unit Alexion, which was recently acquired by AstraZeneca, is being trialled for Wilson’s disease, a genetic condition that interferes with the body’s ability to eliminate copper deposits.
The experimental once-daily oral drug could provide a less invasive option for patients who are typically given treatment that involves injections of metal-removing metals into the blood or zinc therapy.
“As we develop the first innovations in the treatment of Wilson’s disease for more than 30 years, we will continue to monitor these patients long-term to assess further clinical impact on disease symptoms,” said Alexion CEO Marc Dunoyer.